Multiple benefits with multilineage defense1

LEUKINE® (sargramostim) significantly reduced the risk of serious and fatal infection vs placebo in a phase 3, multicenter, randomized, double-blind, placebo-controlled study of patients following induction therapy for AML (N=99)1-3

Significantly decreased incidence of fatal infection1-3

Significantly decreased incidence of fatal infection chart

Significantly decreased incidence of serious infection1-3

Leukine

 
 

versus

(P=0.02)

Placebo

 
 

AML=acute myeloid leukemia.

Full study design

Following allogeneic BMT, patients receiving LEUKINE® (sargramostim) experienced a reduced incidence of infection vs placebo in a multicenter, randomized, placebo-controlled, double-blind study (N=109)1

Significantly reduced incidence of infection1

Incidence of infection (P<0.05)

 
 
 
 

Incidence of Grade 3 and 4 mucositis (P<0.05)

 
 
 
 

Incidence of bacteremia (P<0.05)

 
 
 
 
Full study design

LEUKINE safety and efficacy were evaluated in 3 single-center, randomized, placebo-controlled, double-blind studies of 128 patients undergoing autologous BMT. Efficacy data reflect a subpopulation of patients with NHL or ALL (N=104)1

Significantly reduced duration of infection, antibacterial therapy, and hospitalization1

LEUKINE® (sargramostim) reduced the duration of infection by 75%

vs placebo (1 day vs 4 days, respectively; P<0.05)

4-day reduction

of antibacterial therapy with LEUKINE vs placebo
(21 days vs 25 days, respectively; P<0.05)

6-day reduction

in length of hospitalization with LEUKINE vs placebo
(25 days vs 31 days, respectively; P<0.05)

ALL=acute lymphoblastic leukemia; BMT=bone marrow transplantation; NHL=non-Hodgkin lymphoma.

Full study design

LEUKINE® (sargramostim) provided a median survival benefit vs historical controls in a study of patients experiencing delayed or failed engraftment after allogeneic or autologous BMT1

Median survival benefit after
autologous BMT (N=85)1

474 days with Leukine vs. 161 days historical controls

Median survival benefit after
allogeneic BMT (N=158)1

97 days with Leukine vs. 35 days historical controls

BMT=bone marrow transplantation.

Full study design

Learn about LEUKINE prescribing, efficacy, safety, and more from a LEUKINE specialist

#

Contact PartnerTx for comprehensive information about LEUKINE, including resources that may help your patients with cost of treatment.

Complete the required fields below to connect with a LEUKINE specialist.

    *Indicates required field.










    Take a brief survey about your treatment approaches after transplant

    A donation will be made upon completion of the survey to support patients navigating the transplant journey.

    Take the survey